Insmed | INSM - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
BioMarin Pharmaceutical USD 713.42M 142.21M 2026-06
Cytokinetics USD 23.03M 3.84M 2026-06
DBV Technologies USD 2.77M 33.21M 2025-09
Gilead Sciences USD 6.8B 1.29B 2026-06
Heron Therapeutics USD 29.47M 3.17M 2025-12
Insmed USD 356.19M 99.73M 2026-06
Novartis USD 10.07B 758M 2026-03
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Sarepta Therapeutics USD 251.15M 370.2M 2026-06
Ultragenyx Pharmaceutical USD 180M 74M 2026-06
Vertex Pharmaceuticals USD 2.84B 242.4M 2026-06